Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Anal Chem ; 92(13): 9072-9078, 2020 07 07.
Article in English | MEDLINE | ID: mdl-32484659

ABSTRACT

Plasma-free metanephrines and catecholamines are essential markers in the biochemical diagnosis and follow-up of neuroendocrine tumors and inborn errors of metabolism. However, their low circulating concentrations (in the nanomolar range) and poor fragmentation characteristics hinder facile simultaneous quantification by liquid chromatography and tandem mass spectrometry (LC-MS/MS). Here, we present a sensitive and simple matrix derivatization procedure using propionic anhydride that enables simultaneous quantification of unconjugated l-DOPA, catecholamines, and metanephrines in plasma by LC-MS/MS. Dilution of propionic anhydride 1:4 (v/v) in acetonitrile in combination with 50 µL of plasma resulted in the highest mass spectrometric response. In plasma, derivatization resulted in stable derivatives and increased sensitivity by a factor of 4-30 compared with a previous LC-MS/MS method for measuring plasma metanephrines in our laboratory. Furthermore, propionylation increased specificity, especially for 3-methoxytyramine, by preventing interference from antihypertensive medication (ß-blockers). The method was validated according to international guidelines and correlated with a hydrophilic interaction LC-MS/MS method for measuring plasma metanephrines (R2 > 0.99) and high-performance liquid chromatography with an electrochemical detection method for measuring plasma catecholamines (R2 > 0.85). Reference intervals for l-DOPA, catecholamines, and metanephrines in n = 115 healthy individuals were established. Our work shows that analytes in the subnanomolar range in plasma can be derivatized in situ without any preceding sample extraction. The developed method shows improved sensitivity and selectivity over existing methods and enables simultaneous quantification of several classes of amines.


Subject(s)
Catecholamines/blood , Metanephrine/blood , Tandem Mass Spectrometry/methods , Catecholamines/isolation & purification , Catecholamines/standards , Chromatography, High Pressure Liquid/standards , Dopamine/analogs & derivatives , Dopamine/blood , Dopamine/isolation & purification , Dopamine/standards , Humans , Levodopa/blood , Levodopa/isolation & purification , Levodopa/standards , Limit of Detection , Metanephrine/isolation & purification , Metanephrine/standards , Reference Values , Solid Phase Extraction , Tandem Mass Spectrometry/standards
2.
Forum Health Econ Policy ; 23(2): 1-23, 2020 11 25.
Article in English | MEDLINE | ID: mdl-33984886

ABSTRACT

OBJECTIVES: Quantify the value of functional status (FS) improvements consistent in magnitude with improvements due to levodopa-carbidopa intestinal gel (LCIG) treatment, among the advanced Parkinson's disease (APD) population. METHODS: The Health Economic Medical Innovation Simulation (THEMIS), a microsimulation that estimates future health conditions and medical spending, was used to quantify the health and cost burden of disability among the APD population, and the value of quality-adjusted life-years gained from FS improvement due to LCIG treatment compared to standard of care (SoC). A US-representative Parkinson's disease (PD)-comparable cohort was constructed in THEMIS based on observed PD patient characteristics in a nationally representative dataset. APD was defined from the literature and clinical expert input. The PD and APD cohorts were followed from 2010 over their remaining lifetimes. All individuals were ages 65 and over at the start of the simulation. To estimate the value of FS improvement due to LCIG treatment, decreases in activities of daily living (ADL) limitations caused by LCIG treatment were calculated using data from a randomized, controlled, double-blind, double-dummy clinical trial and applied to the APD population in THEMIS. RESULTS: Total burden of disability associated with APD was $17.7 billion (B). From clinical trial data, LCIG treatment versus SoC lowers the odds of difficulties in walking, dressing, and bathing by 76%, 42% and 39%, respectively. Among the APD population, these reductions generated $2.6B in value to patients and cost savings to payers. The added value was 15% of the burden of disability associated with APD and offsets 15% of the cost of LCIG treatment. CONCLUSIONS: FS improvements, consistent with improvements due to LCIG treatment, in the APD population created health benefits and reduced healthcare costs in the US.


Subject(s)
Activities of Daily Living/psychology , Carbidopa/standards , Levodopa/standards , Parkinson Disease/complications , Parkinson Disease/drug therapy , Social Values , Aged , Aged, 80 and over , Antiparkinson Agents/pharmacology , Antiparkinson Agents/standards , Carbidopa/pharmacology , Drug Combinations , Female , Gels/pharmacology , Gels/standards , Gels/therapeutic use , Humans , Levodopa/pharmacology , Male , Parkinson Disease/psychology
3.
Eur J Pharm Sci ; 123: 475-483, 2018 Oct 15.
Article in English | MEDLINE | ID: mdl-30076956

ABSTRACT

The aim of this work was to carry out preliminary experiments for preparation of levodopa (LEVO)-containing intranasal powder. The experiments were designed according to the Quality by Design (QbD) concept. Based on prior risk assessment, LEVO and chitosan (CH) or sodium hyaluronate (HA) as mucoadhesive matrix formers were co-milled using planetary ball mill to prepare microparticles as drug delivery systems. The rotation speed, the milling time and the drug-additive ratio were evaluated to be the most relevant milling factors - as a result of the initial risk assessment; which were set according to a factorial design. The effects of critical process parameters and excipients were investigated on the particle size and surface characteristics of products, and on the crystallinity, in vitro dissolution and permeability of LEVO. Milling in the presence of higher amount of HA resulted in smaller average particle size of powders (D50 = 13.068 µm) and higher initial dissolution and permeation of LEVO compared to CH-containing formulations (D50 = 21.667 µm).


Subject(s)
Antiparkinson Agents/chemistry , Chemistry, Pharmaceutical/methods , Levodopa/chemistry , Technology, Pharmaceutical/methods , Adhesiveness , Administration, Intranasal , Antiparkinson Agents/administration & dosage , Antiparkinson Agents/standards , Chemistry, Pharmaceutical/standards , Chitosan/chemistry , Crystallization , Delayed-Action Preparations , Drug Carriers , Drug Compounding , Drug Liberation , Hyaluronic Acid/chemistry , Kinetics , Levodopa/administration & dosage , Levodopa/standards , Particle Size , Permeability , Powders , Preliminary Data , Quality Control , Solubility , Technology, Pharmaceutical/standards
4.
Neurodegener Dis Manag ; 6(3): 187-202, 2016 06.
Article in English | MEDLINE | ID: mdl-27075968

ABSTRACT

Patients with Parkinson's disease often have a good initial response to dopaminergic therapy but later usually develop motor fluctuations and dyskinesia. In these patients, continuous infusion of levodopa-carbidopa intestinal gel (LCIG) allows for maintaining adequate dopamine levels and for improving motor and nonmotor symptoms, as well as quality of life and autonomy. Adequate candidate selection and follow-up are crucial for treatment success. Management should be multidisciplinary, and patient and caregiver education is a priority. This expert consensus document has been developed by a team of neurologists, gastroenterologists and nurses who have a vast experience in LCIG therapy, with an intention to provide knowledge and tools to facilitate patient management throughout all phases of LCIG treatment process.


Subject(s)
Antiparkinson Agents/administration & dosage , Carbidopa/administration & dosage , Intestines/drug effects , Levodopa/administration & dosage , Parkinson Disease/drug therapy , Treatment Outcome , Carbidopa/standards , Caregivers/psychology , Clinical Trials as Topic/methods , Clinical Trials as Topic/standards , Databases, Bibliographic/statistics & numerical data , Drug Administration Schedule , Drug Combinations , Female , Follow-Up Studies , Gels/administration & dosage , Gels/standards , Humans , Intestines/physiology , Levodopa/standards , Male
5.
Bioanalysis ; 7(2): 207-20, 2015.
Article in English | MEDLINE | ID: mdl-25587837

ABSTRACT

BACKGROUND: In this study, we developed and validated a HPLC-MS/MS method capable of simultaneously determining levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma. RESULTS & METHODOLOGY: Chromatographic separation was achieved using a C8 column with a mobile phase consisting of a gradient of water and acetonitrile:methanol (90:10 v/v), both containing 0.1% formic acid. The developed method was selective, sensitive (LD<7.0 ng ml(-1)), linear (r>0.99), precise (RSD<11.3%), accurate (RE<11.8%) and free of residual and matrix effects. The developed method was successfully applied in plasma patients with Parkinson's disease using Stalevo®. CONCLUSION: The new method can be used for the clinical monitoring of these substances and applied to adjustments in drug dosages.


Subject(s)
Benzophenones/blood , Blood Chemical Analysis/methods , Carbidopa/blood , Catechols/blood , Chromatography, High Pressure Liquid , Dihydroxyphenylalanine/analogs & derivatives , Dopamine/blood , Levodopa/blood , Nitriles/blood , Nitrophenols/blood , Tandem Mass Spectrometry , Benzophenones/standards , Carbidopa/standards , Catechols/standards , Chromatography, High Pressure Liquid/standards , Dihydroxyphenylalanine/blood , Dihydroxyphenylalanine/standards , Dopamine/standards , Humans , Levodopa/standards , Nitriles/standards , Nitrophenols/standards , Quality Control , Reproducibility of Results , Tandem Mass Spectrometry/standards , Tolcapone , Tyrosine/analogs & derivatives
6.
BMC Pharmacol Toxicol ; 14: 24, 2013 Apr 23.
Article in English | MEDLINE | ID: mdl-23617953

ABSTRACT

BACKGROUND: By definition, a generic product is considered interchangeable with the innovator brand product. Controversy exists about interchangeability, and attention is predominantly directed to contaminants. In particular for chronic, degenerative conditions such as in Parkinson's disease (PD) generic substitution remains debated among physicians, patients and pharmacists. The objective of this study was to compare the pharmaceutical quality of seven generic levodopa/benserazide hydrochloride combination products marketed in Germany with the original product (Madopar® / Prolopa® 125, Roche, Switzerland) in order to evaluate the potential impact of Madopar® generics versus branded products for PD patients and clinicians. METHODS: Madopar® / Prolopa® 125 tablets and capsules were used as reference material. The generic products tested (all 100 mg/25 mg formulations) included four tablet and three capsule formulations. Colour, appearance of powder (capsules), disintegration and dissolution, mass of tablets and fill mass of capsules, content, identity and amounts of impurities were assessed along with standard physical and chemical laboratory tests developed and routinely practiced at Roche facilities. Results were compared to the original "shelf-life" specifications in use by Roche. RESULTS: Each of the seven generic products had one or two parameters outside the specifications. Deviations for the active ingredients ranged from +8.4% (benserazide) to -7.6% (levodopa) in two tablet formulations. Degradation products were measured in marked excess (+26.5%) in one capsule formulation. Disintegration time and dissolution for levodopa and benserazide hydrochloride at 30 min were within specifications for all seven generic samples analysed, however with some outliers. CONCLUSIONS: Deviations for the active ingredients may go unnoticed by a new user of the generic product, but may entail clinical consequences when switching from original to generic during a long-term therapy. Degradation products may pose a safety concern. Our results should prompt caution when prescribing a generic of Madopar®/Prolopa®, and also invite to further investigations in view of a more comprehensive approach, both pharmaceutical and clinical.


Subject(s)
Benserazide/standards , Capsules/standards , Drugs, Generic/standards , Levodopa/standards , Tablets/standards , Benserazide/pharmacokinetics , Benserazide/therapeutic use , Capsules/chemistry , Color , Dopamine Agents/pharmacokinetics , Dopamine Agents/standards , Dopamine Agents/therapeutic use , Drug Combinations , Drugs, Generic/pharmacokinetics , Drugs, Generic/therapeutic use , Humans , Levodopa/pharmacokinetics , Levodopa/therapeutic use , Parkinson Disease/drug therapy , Practice Patterns, Physicians'/standards , Product Surveillance, Postmarketing/methods , Product Surveillance, Postmarketing/statistics & numerical data , Quality Control , Tablets/chemistry , Therapeutic Equivalency
SELECTION OF CITATIONS
SEARCH DETAIL
...